Systemic sclerosis: New evidence re-enforces the role of B cells

Autoimmunity Reviews

Volumn 15, Issue 2, 2016, Pages 155-161

  Sakkas, Lazaros I ^a,b   Bogdanos, Dimitrios P ^a,c  

^a UNIVERSITY OF THESSALY   (Greece)

^b OLD DOMINION UNIVERSITY   (United States)

^c KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Autoantibodies; B cells; Bregs; Fibrosis; Systemic sclerosis; Vasoconstriction

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; AUTOANTIBODY; B CELL ACTIVATING FACTOR; B LYMPHOCYTE RECEPTOR; BLEOMYCIN; BONE MORPHOGENETIC PROTEIN; CD19 ANTIGEN; CD22 ANTIGEN; COLLAGEN; ENDOTHELIN 1; ENDOTHELIN 1 TYPE A RECEPTOR; INTERLEUKIN 10; INTERLEUKIN 6; INTERLEUKIN 8; INTERSTITIAL COLLAGENASE; MONOCYTE CHEMOTACTIC PROTEIN 1; REACTIVE OXYGEN METABOLITE; RITUXIMAB; STROMELYSIN; TOLL LIKE RECEPTOR 9; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANTIGEN PRESENTING CELL; AUTOIMMUNE DISEASE; B LYMPHOCYTE; B LYMPHOCYTE ACTIVATION; CELL CONTACT; CELL MATURATION; CELL THERAPY; CHRONIC GRAFT VERSUS HOST DISEASE; CYTOKINE PRODUCTION; DENDRITIC CELL; ENDOTHELIUM CELL; FIBROBLAST; GENE OVEREXPRESSION; HUMORAL IMMUNE DEFICIENCY; LUNG FUNCTION; MOUSE; NONHUMAN; PATHOGENESIS; PREECLAMPSIA; REGULATORY T LYMPHOCYTE; REVIEW; SIGNAL TRANSDUCTION; SKIN FIBROSIS; SYSTEMIC SCLEROSIS; TH2 CELL; VASOCONSTRICTION; ANIMAL; HUMAN; IMMUNOLOGY; LYMPHOCYTE ACTIVATION;

ANIMALS; ANTIGEN-PRESENTING CELLS; AUTOANTIBODIES; B-LYMPHOCYTES; HUMANS; LYMPHOCYTE ACTIVATION; SCLERODERMA, SYSTEMIC; TH2 CELLS;

EID: 84954324103     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2015.10.005     Document Type: Review

References (86)

1. Sakkas L.I., Chikanza I.C., Platsoucas C.D. Mechanisms of disease: the role of immune cells in the pathogenesis of systemic sclerosis. Nat Clin Pract Rheumatol 2006, 2:679-685.
2. Elhai M., Avouac J., Kahan A., Allanore Y. Systemic sclerosis at the crossroad of polyautoimmunity. Autoimmun Rev 2013, 12:1052-1057.
3. Marie I., Gehanno J.F., Bubenheim M., et al. Prospective study to evaluate the association between systemic sclerosis and occupational exposure and review of the literature. Autoimmun Rev 2014, 13:151-156.
4. Feghali-Bostwick C., Medsger T.A., Wright T.M. Analysis of systemic sclerosis in twins reveals low concordance for disease and high concordance for the presence of antinuclear antibodies. Arthritis Rheum 2003, 48:1956-1963.
5. Prescott R.J., Freemont A.J., Jones C.J., Hoyland J., Fielding P. Sequential dermal microvascular and perivascular changes in the development of scleroderma. J Pathol 1992, 166:255-263.
6. Sgonc R., Gruschwitz M.S., Boeck G., Sepp N., Gruber J., Wick G. Endothelial cell apoptosis in systemic sclerosis is induced by antibody-dependent cell-mediated cytotoxicity via CD95. Arthritis Rheum 2000, 43:2550-2562.
7. van den Hoogen F., Khanna D., Fransen J., et al. 2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League against Rheumatism collaborative initiative. Arthritis Rheum 2013, 65:2737-2747.
8. van den Hoogen F., Khanna D., Fransen J., et al. 2013 classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiative. Ann Rheum Dis 2013, 72:1747-1755.
9. Sakkas L.I., Simopoulou T., Katsiari C., Bogdanos D., Chikanza I.C. Early systemic sclerosis-opportunities for treatment. Clin Rheumatol 2015, 34:1327-1331.
10. Kraling B.M., Maul G.G., Jimenez S.A. Mononuclear cellular infiltrates in clinically involved skin from patients with systemic sclerosis of recent onset predominantly consist of monocytes/macrophages. Pathobiology 1995, 63:48-56.
11. Kalogerou A., Gelou E., Mountantonakis S., Settas L., Zafiriou E., Sakkas L. Early T cell activation in the skin from patients with systemic sclerosis. Ann Rheum Dis 2005, 64:1233-1235.
12. Sondergaard K., Stengaard-Pedersen K., Zachariae H., Heickendorff L., Deleuran M., Deleuran B. Soluble intercellular adhesion molecule-1 (sICAM-1) and soluble interleukin-2 receptors (sIL-2R) in scleroderma skin. Br J Rheumatol 1998, 37:304-310.
13. Sakkas L.I., Xu B., Artlett C.M., Lu S., Jimenez S.A., Platsoucas C.D. Oligoclonal T cell expansion in the skin of patients with systemic sclerosis. J Immunol 2002, 168:3649-3659.
14. Whitfield M.L., Finlay D.R., Murray J.I., et al. Systemic and cell type-specific gene expression patterns in scleroderma skin. Proc Natl Acad Sci U S A 2003, 100:12319-12324.
15. Daoussis D., Liossis S.N., Tsamandas A.C., et al. Experience with rituximab in scleroderma: results from a 1-year, proof-of-principle study. Rheumatology (Oxford) 2010, 49:271-280.
16. Bosello S., De Santis M., Lama G., et al. B cell depletion in diffuse progressive systemic sclerosis: safety, skin score modification and IL-6 modulation in an up to thirty-six months follow-up open-label trial. Arthritis Res Ther 2010, 12:R54.
17. Lafyatis R., O'Hara C., Feghali-Bostwick C.A., Matteson E. B cell infiltration in systemic sclerosis-associated interstitial lung disease. Arthritis Rheum 2007, 56:3167-3168.
18. Hussein M.R., Hassan H.I., Hofny E.R., et al. Alterations of mononuclear inflammatory cells, CD4/CD8+ T cells, interleukin 1beta, and tumour necrosis factor alpha in the bronchoalveolar lavage fluid, peripheral blood, and skin of patients with systemic sclerosis. J Clin Pathol 2005, 58:178-184.
19. Lanteri A., Sobanski V., Langlois C., et al. Serum free light chains of immunoglobulins as biomarkers for systemic sclerosis characteristics, activity and severity. Autoimmun Rev 2014, 13:974-980.
20. Mavropoulos A., Simopoulou T., Varna A., et al. B regulatory cells are decreased and functionally impaired in patients with systemic sclerosis. Arthritis Rheum 2015, (in press). 10.1002/art.39437.
21. Sato S., Hasegawa M., Fujimoto M., Tedder T.F., Takehara K. Quantitative genetic variation in CD19 expression correlates with autoimmunity. J Immunol 2000, 165:6635-6643.
22. Matsushita T., Hasegawa M., Yanaba K., Kodera M., Takehara K., Sato S. Elevated serum BAFF levels in patients with systemic sclerosis: enhanced BAFF signaling in systemic sclerosis B lymphocytes. Arthritis Rheum 2006, 54:192-201.
23. Odaka M., Hasegawa M., Hamaguchi Y., et al. Autoantibody-mediated regulation of B cell responses by functional anti-CD22 autoantibodies in patients with systemic sclerosis. Clin Exp Immunol 2010, 159:176-184.
24. Allen J.L., Fore M.S., Wooten J., et al. B cells from patients with chronic GVHD are activated and primed for survival via BAFF-mediated pathways. Blood 2012, 120:2529-2536.
25. Saito E., Fujimoto M., Hasegawa M., et al. CD19-dependent B lymphocyte signaling thresholds influence skin fibrosis and autoimmunity in the tight-skin mouse. J Clin Invest 2002, 109:1453-1462.
26. Duncan M.R., Berman B. Stimulation of collagen and glycosaminoglycan production in cultured human adult dermal fibroblasts by recombinant human interleukin 6. J Invest Dermatol 1991, 97:686-692.
27. O'Reilly S., Ciechomska M., Cant R., van Laar J.M. Interleukin-6 (IL-6) trans signaling drives a STAT3-dependent pathway that leads to hyperactive transforming growth factor-beta (TGF-beta) signaling promoting SMAD3 activation and fibrosis via Gremlin protein. J Biol Chem 2014, 289:9952-9960.
28. Sato S., Hasegawa M., Takehara K. Serum levels of interleukin-6 and interleukin-10 correlate with total skin thickness score in patients with systemic sclerosis. J Dermatol Sci 2001, 27:140-146.
29. Scala E., Pallotta S., Frezzolini A., et al. Cytokine and chemokine levels in systemic sclerosis: relationship with cutaneous and internal organ involvement. Clin Exp Immunol 2004, 138:540-546.
30. Desallais L., Avouac J., Frechet M., et al. Targeting IL-6 by both passive or active immunization strategies prevents bleomycin-induced skin fibrosis. Arthritis Res Ther 2014, 16:R157.
31. Snapper C.M., Waegell W., Beernink H., Dasch J.R. Transforming growth factor-beta 1 is required for secretion of IgG of all subclasses by LPS-activated murine B cells in vitro. J Immunol 1993, 151:4625-4636.
32. Henault J., Robitaille G., Senecal J.L., Raymond Y. DNA topoisomerase I binding to fibroblasts induces monocyte adhesion and activation in the presence of anti-topoisomerase I autoantibodies from systemic sclerosis patients. Arthritis Rheum 2006, 54:963-973.
33. Walker U.A., Tyndall A., Czirjak L., et al. Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials And Research group database. Ann Rheum Dis 2007, 66:754-763.
34. Fineschi S., Goffin L., Rezzonico R., et al. Antifibroblast antibodies in systemic sclerosis induce fibroblasts to produce profibrotic chemokines, with partial exploitation of toll-like receptor 4. Arthritis Rheum 2008, 58:3913-3923.
35. Villalta D., Imbastaro T., Di Giovanni S., et al. Diagnostic accuracy and predictive value of extended autoantibody profile in systemic sclerosis. Autoimmun Rev 2012, 12:114-120.
36. Mahler M., Fritzler M.J., Satoh M. Autoantibodies to the mitochondrial RNA processing (MRP) complex also known as Th/To autoantigen. Autoimmun Rev 2015, 14:254-257.
37. Baroni S.S., Santillo M., Bevilacqua F., et al. Stimulatory autoantibodies to the PDGF receptor in systemic sclerosis. N Engl J Med 2006, 354:2667-2676.
38. Svegliati S., Olivieri A., Campelli N., et al. Stimulatory autoantibodies to PDGF receptor in patients with extensive chronic graft-versus-host disease. Blood 2007, 110:237-241.
39. Sato S., Hayakawa I., Hasegawa M., Fujimoto M., Takehara K. Function blocking autoantibodies against matrix metalloproteinase-1 in patients with systemic sclerosis. J Invest Dermatol 2003, 120:542-547.
40. Nishijima C., Hayakawa I., Matsushita T., et al. Autoantibody against matrix metalloproteinase-3 in patients with systemic sclerosis. Clin Exp Immunol 2004, 138:357-363.
41. Bordron A., Dueymes M., Levy Y., et al. The binding of some human antiendothelial cell antibodies induces endothelial cell apoptosis. J Clin Invest 1998, 101:2029-2035.
42. Wolf S.I., Howat S., Abraham D.J., Pearson J.D., Lawson C. Agonistic anti-ICAM-1 antibodies in scleroderma: activation of endothelial pro-inflammatory cascades. Vascul Pharmacol 2013, 59:19-26.
43. Kill A., Tabeling C., Undeutsch R., et al. Autoantibodies to angiotensin and endothelin receptors in systemic sclerosis induce cellular and systemic events associated with disease pathogenesis. Arthritis Res Ther 2014, 16:R29.
44. Xia Y., Kellems R.E. Angiotensin receptor agonistic autoantibodies and hypertension: preeclampsia and beyond. Circ Res 2013, 113:78-87.
45. Becker M.O., Kill A., Kutsche M., et al. Vascular receptor autoantibodies in pulmonary arterial hypertension associated with systemic sclerosis. Am J Respir Crit Care Med 2014, 190:808-817.
46. Riemekasten G., Philippe A., Nather M., et al. Involvement of functional autoantibodies against vascular receptors in systemic sclerosis. Ann Rheum Dis 2011, 70:530-536.
47. Avouac J., Riemekasten G., Meune C., Ruiz B., Kahan A., Allanore Y. Autoantibodies against Endothelin 1 Type A receptor are strong predictors of digital ulcers in systemic sclerosis. J Rheumatol 2015, 42:1801-1807.
48. Zhou C.C., Zhang Y., Irani R.A., et al. Angiotensin receptor agonistic autoantibodies induce pre-eclampsia in pregnant mice. Nat Med 2008, 14:855-862.
49. Kawaguchi Y., Takagi K., Hara M., et al. Angiotensin II in the lesional skin of systemic sclerosis patients contributes to tissue fibrosis via angiotensin II type 1 receptors. Arthritis Rheum 2004, 50:216-226.
50. Zhou X., Tan F.K., Milewicz D.M., Guo X., Bona C.A., Arnett F.C. Autoantibodies to fibrillin-1 activate normal human fibroblasts in culture through the TGF-beta pathway to recapitulate the "scleroderma phenotype". J Immunol 2005, 175:4555-4560.
51. Muryoi T., Kasturi K.N., Kafina M.J., et al. Antitopoisomerase I monoclonal autoantibodies from scleroderma patients and tight skin mouse interact with similar epitopes. J Exp Med 1992, 175:1103-1109.
52. Lunardi C., Bason C., Navone R., et al. Systemic sclerosis immunoglobulin G autoantibodies bind the human cytomegalovirus late protein UL94 and induce apoptosis in human endothelial cells. Nat Med 2000, 6:1183-1186.
53. Flores-Borja F., Bosma A., Ng D., et al. CD19+CD24hiCD38hi B cells maintain regulatory T cells while limiting TH1 and TH17 differentiation. Sci Transl Med 2013, 5. [173ra123].
54. Shen P., Roch T., Lampropoulou V., et al. IL-35-producing B cells are critical regulators of immunity during autoimmune and infectious diseases. Nature 2014, 507:366-370.
55. Wang R.X., Yu C.R., Dambuza I.M., et al. Interleukin-35 induces regulatory B cells that suppress autoimmune disease. Nat Med 2014, 20:633-641.
56. Tedder T.F. B10 cells: a functionally defined regulatory B cell subset. J Immunol 2015, 194:1395-1401.
57. Blair P.A., Norena L.Y., Flores-Borja F., et al. CD19(+)CD24(hi)CD38(hi) B cells exhibit regulatory capacity in healthy individuals but are functionally impaired in systemic Lupus Erythematosus patients. Immunity 2010, 32:129-140.
58. Iwata Y., Matsushita T., Horikawa M., et al. Characterization of a rare IL-10-competent B-cell subset in humans that parallels mouse regulatory B10 cells. Blood 2011, 117:530-541.
59. Matsushita T., Hamaguchi Y., Hasegawa M., Takehara K., Fujimoto M. Decreased levels of regulatory B cells in patients with systemic sclerosis: association with autoantibody production and disease activity. Rheumatology (Oxford) 2015, (Epub ahead of print) PMID:26350483.
60. Khoder A., Sarvaria A., Alsuliman A., et al. Regulatory B cells are enriched within the IgM memory and transitional subsets in healthy donors but are deficient in chronic GVHD. Blood 2014, 124:2034-2045.
61. Aybar L.T., McGregor J.G., Hogan S.L., et al. Reduced CD5(+) CD24(hi) CD38(hi) and interleukin-10(+) regulatory B cells in active anti-neutrophil cytoplasmic autoantibody-associated vasculitis permit increased circulating autoantibodies. Clin Exp Immunol 2015, 180:178-188.
62. Maddur M.S., Sharma M., Hegde P., et al. Human B cells induce dendritic cell maturation and favour Th2 polarization by inducing OX-40 ligand. Nat Commun 2014, 5:4092.
63. Beland K., Marceau G., Labardy A., Bourbonnais S., Alvarez F. Depletion of B cells induces remission of autoimmune hepatitis in mice through reduced antigen presentation and help to T cells. Hepatology 2015, 62:1511-1523.
64. Crawford A., Macleod M., Schumacher T., Corlett L., Gray D. Primary T cell expansion and differentiation in vivo requires antigen presentation by B cells. J Immunol 2006, 176:3498-3506.
65. Leon B., Ballesteros-Tato A., Lund F.E. Dendritic cells and B cells: unexpected partners in Th2 development. J Immunol 2014, 193:1531-1537.
66. Dwyer D.F., Woodruff M.C., Carroll M.C., Austen K.F., Gurish M.F. B cells regulate CD4+ T cell responses to papain following B cell receptor-independent papain uptake. J Immunol 2014, 193:529-539.
67. Amedei A., Romagnani C., Benagiano M., et al. Preferential Th1 profile of T helper cell responses in X-linked (Bruton's) agammaglobulinemia. Eur J Immunol 2001, 31:1927-1934.
68. Le Huu D., Matsushita T., Jin G., et al. Donor-derived regulatory B cells are important for suppression of murine sclerodermatous chronic graft-versus-host disease. Blood 2013, 121:3274-3283.
69. Le Huu D., Matsushita T., Jin G., et al. IL-6 blockade attenuates the development of murine sclerodermatous chronic graft-versus-host disease. J Invest Dermatol 2012, 132:2752-2761.
70. Asano N., Fujimoto M., Yazawa N., et al. B Lymphocyte signaling established by the CD19/CD22 loop regulates autoimmunity in the tight-skin mouse. Am J Pathol 2004, 165:641-650.
71. Matsushita T., Fujimoto M., Hasegawa M., et al. BAFF antagonist attenuates the development of skin fibrosis in tight-skin mice. J Invest Dermatol 2007, 127:2772-2780.
72. Yoshizaki A., Iwata Y., Komura K., et al. CD19 regulates skin and lung fibrosis via Toll-like receptor signaling in a model of bleomycin-induced scleroderma. Am J Pathol 2008, 172:1650-1663.
73. Komura K., Yanaba K., Horikawa M., et al. CD19 regulates the development of bleomycin-induced pulmonary fibrosis in a mouse model. Arthritis Rheum 2008, 58:3574-3584.
74. Asano Y., Sato S. Animal models of scleroderma: current state and recent development. Curr Rheumatol Rep 2013, 15:382.
75. Jordan S., Distler J.H., Maurer B., et al. Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group. Ann Rheum Dis 2015, 74:1188-1194.
76. Giuggioli D., Lumetti F., Colaci M., Fallahi P., Antonelli A., Ferri C. Rituximab in the treatment of patients with systemic sclerosis. Our experience and review of the literature. Autoimmun Rev 2015, 14:1072-1078.
77. Smith V., Van Praet J.T., Vandooren B., et al. Rituximab in diffuse cutaneous systemic sclerosis: an open-label clinical and histopathological study. Ann Rheum Dis 2010, 69:193-197.
78. Lafyatis R., Kissin E., York M., et al. B cell depletion with rituximab in patients with diffuse cutaneous systemic sclerosis. Arthritis Rheum 2009, 60:578-583.
79. McGonagle D., Tan A.L., Madden J., et al. Successful treatment of resistant scleroderma-associated interstitial lung disease with rituximab. Rheumatology (Oxford) 2008, 47:552-553.
80. Daoussis D., Tsamandas A.C., Liossis S.N., et al. B-cell depletion therapy in patients with diffuse systemic sclerosis associates with a significant decrease in PDGFR expression and activation in spindle-like cells in the skin. Arthritis Res Ther 2012, 14:R145.
81. Hasegawa M., Hamaguchi Y., Yanaba K., et al. B-lymphocyte depletion reduces skin fibrosis and autoimmunity in the tight-skin mouse model for systemic sclerosis. Am J Pathol 2006, 169:954-966.
82. Shima Y., Kuwahara Y., Murota H., et al. The skin of patients with systemic sclerosis softened during the treatment with anti-IL-6 receptor antibody tocilizumab. Rheumatology (Oxford) 2010, 49:2408-2412.
83. Molina V., Haj-Yahia S., Solodeev I., Levy Y., Blank M., Shoenfeld Y. Immunomodulation of experimental pulmonary fibrosis by intravenous immunoglobulin (IVIG). Autoimmunity 2006, 39:711-717.
84. Cantarini L., Rigante D., Vitale A., et al. Intravenous immunoglobulins (IVIG) in systemic sclerosis: a challenging yet promising future. Immunol Res 2015, 61:326-337.
85. Blank M., Bashi T., Shoenfeld Y. Idiotype-specific intravenous immunoglobulin (IVIG) for therapy of autoimmune diseases. Methods Mol Biol 2014, 1060:353-361.
86. Yoshizaki A., Miyagaki T., DiLillo D.J., et al. Regulatory B cells control T-cell autoimmunity through IL-21-dependent cognate interactions. Nature 2012, 491:264-268.